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Active integration: new strategies for transgenesis
Abstract
This paper presents novel methods for producing transgenic animals, with a further emphasis on how
these techniques may someday be applied in gene therapy. There are several passive methods for
transgenesis, such as pronuclear microinjection (PNI) and Intracytoplasmic Sperm Injection-Mediated
Transgenesis (ICSI-Tr), which rely on the repair mechanisms of the host for transgene (tg) insertion.
ICSI-Tr has been shown to be an effective means of creating transgenic animals with a transfection
efficiency of approximately 45% of animals born. Furthermore, because this involves the injection of
the transgene into the cytoplasm of oocytes during fertilization, limited mosaicism has traditionally
occurred using this technique. Current active transgenesis techniques involve the use of viruses, such as
disarmed retroviruses which can insert genes into the host genome. However, these methods are limited
by the size of the sequence that can be inserted, high embryo mortality, and randomness of insertion. A
novel active method has been developed which combines ICSI-Tr with recombinases or transposases to
increase transfection efficiency. This technique has been termed "Active Transgenesis" to imply that the
tg is inserted into the host genome by enzymes supplied into the oocyte during tg introduction. DNA
based methods alleviate many of the costs and time associated with purifying enzyme. Further studies
have shown that RNA can be used for the transposase source. Using RNA may prevent problems with
continued transposase activity that can occur if a DNA transposase is integrated into the host genome.
At present piggyBac is the most effective transposon for stable integration in mammalian systems and as
further studies are done to elucidate modifications which improve piggyBac's specificity and efficacy,
efficiency in creating transgenic animals should improve further. Subsequently, these methods may
someday be used for gene therapy in humans.
PERSPECTIVE
Active integration: new strategies for transgenesis
Eric T. Shinohara Æ Joseph M. Kaminski Æ David J. Segal Æ Pawel Pelczar Æ
Ravindra Kolhe Æ Thomas Ryan Æ Craig J. Coates Æ Malcolm J. Fraser Æ
Alfred M. Handler Æ Ryuzo Yanagimachi Æ Stefan Moisyadi
Accepted: 27 January 2007 / Published online: 6 March 2007
 Springer Science+Business Media B.V. 2007
Abstract This paper presents novel methods for
producing transgenic animals, with a further
emphasis on how these techniques may someday
be applied in gene therapy. There are several
passive methods for transgenesis, such as pronu-
clear microinjection (PNI) and Intracytoplasmic
Sperm Injection-Mediated Transgenesis (ICSI-
Tr), which rely on the repair mechanisms of the
host for transgene (tg) insertion. ICSI-Tr has been
shown to be an effective means of creating
transgenic animals with a transfection efficiency
of approximately 45% of animals born. Further-
more, because this involves the injection of the
transgene into the cytoplasm of oocytes during
fertilization, limited mosaicism has traditionally
occurred using this technique. Current active
transgenesis techniques involve the use of viruses,
such as disarmed retroviruses which can insert
genes into the host genome. However, these
methods are limited by the size of the sequence
that can be inserted, high embryo mortality, and
randomness of insertion. A novel active method
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has been developed which combines ICSI-Tr with
recombinases or transposases to increase trans-
fection efficiency. This technique has been termed
‘‘Active Transgenesis’’ to imply that the tg is
inserted into the host genome by enzymes sup-
plied into the oocyte during tg introduction. DNA
based methods alleviate many of the costs and
time associated with purifying enzyme. Further
studies have shown that RNA can be used for the
transposase source. Using RNA may prevent
problems with continued transposase activity that
can occur if a DNA transposase is integrated into
the host genome. At present piggyBac is the most
effective transposon for stable integration in
mammalian systems and as further studies are
done to elucidate modifications which improve
piggyBac’s specificity and efficacy, efficiency in
creating transgenic animals should improve fur-
ther. Subsequently, these methods may someday
be used for gene therapy in humans.
Keywords Transposon  Transposase 
Site-specific  Retrovirus  Recombinase
Introduction
The transgenic methods in use today were devel-
oped in the past 25 years and these traditional
methods of genetic engineering and transgenesis
insert genes at random locations within the large
genome of higher organisms, resulting in loss of
efficiency, unpredictable results, and unintended
genetic consequences (Perry et al. 1999; Wall
2001; Lois et al. 2002; Wall 2002). The pronuclear
microinjection technique was the first to be
conceived and was developed specifically to
produce germline transgenic mice. It has gener-
ated transgenic animals in a wide variety of
mammalian species, usually with multiple concat-
emerised vector copies (Muller 1999; Wall 2001).
The most efficient transgenesis method to date
is an active form of transgenesis which utilizes a
Lentiviral technique first developed in rodents
and later extended to farm animals (Lois et al.
2002; Hofmann et al. 2003). It makes use of
disarmed retroviral vectors to actively insert
desirable genes into the host organism, usually
at the single celled embryo stage (Lois et al.
2002). However, there are several major draw-
backs of this technique, such as the high embryo
lethality (73%) and the relatively small amount of
transgene (tg) DNA (9.5 kb) that can be trans-
ported, due to the limited physical volume of the
viral particles (Lois et al. 2002). This, coupled
with the required specialized containment facili-
ties for retroviral production, make it prohibitive
for many laboratories to exercise the retroviral
transgenesis approach (Wall 2002). There are also
concerns about the potential consequences of
recombinant events between the viral vector and
endogenous retroviruses, leading to the genera-
tion of new, more potent pathogenic agents.
Intracytoplasmic sperm injection-mediated
transgenesis
The Institute for Biogenesis Research (IBR) at
the University of Hawai’i in Manoa, developed
another passive technique for the production of
transgenic mice called Intracytoplasmic Sperm
Injection-Mediated Transgenesis (ICSI-Tr) (Per-
ry et al. 1999). During ICSI-Tr mouse spermato-
zoa are demembranated either by freeze-thawing
or by treatment with TritonX-100, then incubated
with linear, double stranded (ds) DNA that
contains the tg. The rationale for this method
was that the exposed perinuclear theca of the
sperm head would interact with the DNA and act
as a carrier for the tg. This sperm-DNA complex
is then injected into oocytes by ICSI, and the tg is
incorporated into the embryonic genome via the
DNA repair mechanism (Perry 2000). During
ICSI-Tr, the transfection efficiency is on average,
2.5% of oocytes injected (oi) or 20% of animals
born (ab), with very little mosaicism (Perry et al.
1999). Recently a more efficient version of this
method was reported where the efficiencies of oi
and ab are 4.6% and 45%, respectively (Moreira
et al. 2004). Both techniques, however, are
examples of passive transgenesis procedures,
which rely on the repair mechanism of the zygote
for tg insertion. The ICSI-Tr techniques never-
theless have resulted in the insertion of tg in the
region of >200 kb (Perry et al. 2001; Moreira
et al. 2004; Osada et al. 2005).
To address some of the concerns noted above, a
series of ICSI transgenesis methods have been
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developed in which enzymes are used to facilitate
the tg insertion. ICSI-Tr’s reliance on the repair
mechanisms of the zygote nucleus for the insertion
of a tg limits the efficiency and specificity of this
technique (Perry et al. 1999), and it has an
efficiency of at best only 4.6% of oocytes injected
resulting in transgenic mice (Moreira et al. 2004).
To improve the efficiency of this method of
transgenesis, an approach termed ‘‘Active Trans-
genesis’’ has been used. In this method, recombin-
ases or transposases are injected into mouse
oocytes to increase the efficiency of transgene
integration into the genome. We have demon-
strated that the bacterial recombinase protein
RecA (Kaneko et al. 2005) and a mutated hyper-
active Tn5 transposase protein (*Tn5p) (Suga-
numa et al. 2005) both increase transgenesis
several fold as compared to conventional methods
such as pronuclear microinjection (Nakanishi et al.
2002) and traditional ICSI-Tr (Perry et al. 1999).
Active transgenesis
The term ‘‘Active Transgenesis’’ was selected to
imply that the tg is inserted into the host genome
by enzymes supplied into the oocyte during tg
introduction. Among approaches utilizing protein
recombinases (RecA) (Kaneko et al. 2005) or
transposases, the hyperactive Tn5 transposase
protein (*Tn5p) was by far the most efficient
method for introducing the tg in a transposon
along with spermatozoa into unfertilized oocytes
(TN:ICSI) (Suganuma et al. 2005). In our hands,
this approach dramatically increased the effi-
ciency of producing transgenic mice, with 11%
of eggs injected and 22% of live births resulting in
transmission of the tg DNA and over 75% of
transgenic mice expressing the EGFP tg. Of these
transgenic mice, 25% had one or two copies of
the tg inserted in their genome. However,
TN:ICSI methods suffer from cumbersome en-
zyme preparation techniques. A rich protein
source is required, which in some cases is com-
mercially available. DNA is much easier and
faster to purify as compared to protein. Tech-
niques to fractionate the source material must
also not destroy the activity of the enzyme and an
effective and sensitive assay for activity is
required to check for purity. These factors
contribute to the time and expense of enzymatic
purification compared with DNA based proce-
dures. Due to this, we have now moved away
from the enzymatic insertions of tg and developed
DNA and RNA based procedures that allow
synthesis of the transposase in-situ.
We are now able to produce transgenic animals
using active transgenesis with similar efficiencies
as retroviral methods (Table 1). However, the F0
mice produced appear mosaic, because transcrip-
tion may occur after the one cell stage (Fig. 1).
We might solve this by injecting cRNA to obtain
transposase expression at the one cell embryo
stage. Alternatively, epigenetic silencing could be
occuring in certain tissues. We have also con-
structed transgenic ready mice containing the
transposase under the control of the shortened
Zona Pellucida 3 promoter (sZP3p), which would
simplify ICSI-Tr and pronuclear techniques, by
allowing transposase expression exclusively in the
growing oocyte prior to the completion of the
second meiotic division (Fig. 2).
There are potential hazards in using a DNA
transposase for the integration of the tg. If the
DNA transposase is stably integrated into the
host DNA and expressed this could lead to
remobilization of transposons and reintegration.
The continued mobilization of the tg could lead to
deleterious genomic modifications. A means of
preventing this is through the use cRNA as the
Table 1 piggyBac:ICSI efficiency versus Lentiviral, pro-
nuclear microinjection and ICSI-Tr















The percent of oocytes which are successfully transfected
using various delivery methods are shown (Oi). Also
shown are the percentages of successfully transfected
animals which are born (Ab) using various delivery
methods. Transfection rates with PgB:ICSI are
comparable to Lentiviral Vectors in both percentage of
oocytes transfected and animals born
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source for the transposase enzymatic activity,
which has been shown to be effective (Wilber
et al. 2006). The transient nature of cRNA, limits
the duration of transposase activity and would
likely attenuate the risks of the integration of the
transposase into the host genome. However, it is
theoretically possible, although unlikely, that the
RNA could undergo reverse transcription
resulting in the possibility of non-homologous
recombination into the host genome.
To determine which DNA transposase encod-
ing plasmids may have the greatest affect on tg
insertion, four commonly used transposon trans-
fection systems were studied in four different
mammalian cell lines (Wu et al. 2006), three of
which were human. These initial experiments
performed with the two plasmid system (Donor
and Helper plasmids) demonstrated that piggy-
Bac (PB), a transposase isolated from the cab-
bage looper moth Trichoplusia ni, and found to
exhibit activity in a variety of species ranging
from planarian to mammalian cells (Lobo et al.
2006), is the most effective mediator for stable
insertion of tg’s in all cell lines tested. One
potential limitation of transposases is that instead
of reaching a plateau in transposition with
increasing transposase, transposon integration
declines due to overproduction inhibition. We
have observed overproduction inhibition with PB
and it might also occur with Tol2 if the ratio of
helper to donor plasmid was increased (Wu et al.
2006). In contrast, Wilson and colleagues did not
demonstrate overproduction inhibition with PB
(Wilson et al. 2007). PB and Tol2 have been
found to be able to carry a larger cargo as
compared to Sleeping Beauty (SB). For example,
the PB helper can be large (9.3–14.3 Kb) without
significant reduction in transposition efficiency
(Ding et al. 2005). Transposon systems have many
attractive features as vectors for gene delivery,
such as: (a) accommodating large tg; (b) being
non-viral, they do not induce an immune response
in rodent models; (c) inexpensive to mass produce
(Kaminski and Summers 2003) and (d) mediating
efficient tg integration which is stable and shows
persistent expression (Ivics et al. 1997).
Mechanisms to improve specificity and efficiency
of transfection
As PB is the most efficient transposon in mam-
malian systems (Wu et al. 2006), studies to modify
PB to increase its specificity and transposition
efficiency are in progress. Until recently the PB
literature described the transposition machinery
as a two-component system: a Helper plasmid
Fig. 1 All F0 pups born are mosaics because transcription
from the introduced piggyBac plasmid might not com-
mence until after the first cell division. Therefore, for both
ICSI and pronuclear microinjected embryos, only cells that
have inherited the donor–helper plasmid express EGFP.
Alternatively, epigenetic silencing could be occuring in
certain tissues
Fig. 2 The oocyte donor females are homozygous for the
shortened ZP3 promoter driven bicistronic cassette. The
sZP3 promoter is active only during oocyte development
and oocytes transgenic for the piggyBac transposase are
recognizable by EGFP expression. At metaphase II stage
arrested oocytes are loaded with the piggyBac transposase
protein and the transgene offered to them by the donor
plasmid is readily inserted into the single cell embryo
genome
336 Transgenic Res (2007) 16:333–339
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containing the transposase and a Donor plasmid
containing the transposon (Wilson et al. 2007).
We and recently others have simplified this
approach by including the Helper and Donor
components of PB in a single plasmid. This single
plasmid approach makes it easier to effect trans-
position where if the plasmid has entered the
nucleus of a cell, both components are included in
it, likely facilitating transposition (Mikkelsen
et al. 2003; Wilson et al. 2007) (Kaminski and
Moisyadi, Unpublished). There is currently work
being done with PB transposase to increase the
transpositional efficiencies to that of retroviral
vectors. There are methods to accomplish this
goal such as PCR random mutagenesis or alanine
substitutions utilizing mutagenic PCR primers
(Goryshin and Reznikoff 1998; Yant et al. 2004;
Pledger and Coates 2005; Keravala et al. 2006).
One of us, Thomas Ryan, is pursuing PB active
transgenesis in embryonic stem cells for the
production of transgenic animals.
Other alterations include creating chimeric
integrating enzymes for targeted integration.
Chimeric transposons have significant advantages
over site-specific retroviral vectors. For example,
some transposases and other integrating enzymes
(such as some serine recombinases) have a
natural division into two domains (a catalytic
domain that performs the DNA insertion, and a
DNA directing domain which juxtaposes the
integrating enzyme to the host DNA). Thus,
some are likely amenable to chimeric approaches
that swap the DNA-directing domain for one that
targets the integrating enzyme to any chosen host
DNA sequence. In certain integrating enzymes,
e.g. transposases, the catalytic domains have little
or no natural site specificity; therefore, it princi-
pally would be the engineered DNA binding
domain that governs the site-specificity in chime-
ric integrating enzymes (Kaminski et al. 2002).
Integrating enzymes such as from SB, PB, and/or
uC31 have been widely used in plants, animals,
insects, prokaryotes and frequently their usage is
not limited to specific species (Coates et al. 2005;
Kolb et al. 2005). The technology used to engi-
neer the specific DNA binding domains is well
defined, and has very flexible sequence specificity
(Kolb et al. 2005). Transposases recognize loose
consensus sequences, e.g. Tc1 superfamily
integrate into TA dinucleotides, whereas site-
specific recombinases recognize and mediate the
recombination between short, well characterized
DNA sequences resulting in the integration,
excision or inversion of DNA fragments. Trans-
posases have a theoretical advantage over recom-
binases in that they are potentially amenable to
target any given region whereas recombinases are
inherently limited to specific or closely related
(pseudo) sites due to specific, larger sequence
requirements of the catalytic domain. Thus, chi-
meric transposases could allow us to design
vectors that would integrate into or around any
site assuming the chromatin in that region is
permissive for integration. Some recombinases,
i.e. serine recombinases, allow unidirectional,
irreversible integration and are limited to fewer
sites, but can result in high frequencies of chro-
mosomal rearrangements (Malla et al. 2005; Ehr-
hardt et al. 2006). We have tried to alter uC31
recombinase by coupling it to a DNA binding
domain to target a specific pseudo-site but this
resulted in loss of activity. In contrast, we have
altered the PB transposase to direct integration
and it has retained full activity (Wu et al. 2006).
Recent studies with PB and Mos1 have shown
promising results for targeted integration. A
Gal4-piggybac and Gal4-Mos1 chimera resulted
in approximately a 11.6 and 12.7 fold increase,
respectively, in targeted integration into a plas-
mid which contained a UAS tandem array
(GAL4 binding site), presumably through tether-
ing the transposon–transposase complex at the
target site. There was a high level of specificity
with the GAL4-Mos1 chimera with 51/53 recov-
ered transposition events occurring at a single TA
target site in the UAS plasmid and all but one
were in the 5¢-3¢ orientation. In the Gal4-piggy-
Bac chimera 45/67 inserted into a single TTAA
target site and 36 of them were in the 5¢-3¢
orientation. These results suggest that the Gal4-
UAS limits the number of target sites at which
integration can occur, likely due to the tethering
of the transposase close to the UAS target
(Maragathavally et al. 2006). Mos1 does not appear
to be functional in mammalian systems (Wu et al.
2006). However, the PB transposase coupled to the
GAL4 DNA binding domain retains transposition
activity similar to the wild-type, unlike Tol2 or
Transgenic Res (2007) 16:333–339 337
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SB. Thus, we have recently constructed a
transgenic mouse containing a genomic UAS
tandem array and experiments are on-going to
determine whether we preferentially target
this region and if integration efficiencies are
enhanced. We will also be testing the ability of a
six-zinc finger domain to direct the integration of a
transposon to an endogenous locus. The general
strategy will be to direct integration to a gene that,
when disrupted, will produce a phenotypic change
for easy analysis but not adversely affect the health
of the mouse. The tyrosinase (Tyr) gene, located on
chromosome 7, would be one potential target. TYR
is an enzyme present in melanocytes that catalyzes
the production of melanin and other pigments from
tyrosine by oxidation. Mutations in the Tyr gene
result in albinism. In order to knock-out TYR
function, a transposon gene trap vector with a
splice acceptor site will be constructed so that it can
integrate anywhere within the tyrosinase locus to
create a knock-out of that gene’s product. Since
loss of pigmentation would not be anticipated to
adversely affect the health of the mouse or the cell,
this locus is considered a ‘‘safe’’ genomic location
for testing targeted transposition.
Conclusions
By using transposons in conjunction with the
passive technique ISCI-Tr, active transgenesis has
been shown to greatly improve the rate and
specificity of the insertion of tg. By providing the
transposase (RNA, protein, or early expression
from the ZP3) at the one cell stage, the rate of
mosaicism should be reduced to allow for uniform
expression of the tg throughout the host tissue.
RNA has one major advantage, because the
transposase source cannot integrate into the
genome, thus transposase activity will always be
transient. As further refinements are made to the
transposases used, greater specificity and effi-
ciency can be achieved. These techniques will
reduce the cost, time, and unpredictability in the
production of transgenic animals. Once there has
been greater experience with creating transgenic
animals these techniques might be used in human
gene therapy.
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